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MMP activity can contribute to pathology related to conditions including atheroma, 4 arthritis, 5 and cancer, 6 with central roles in tissue remodelling, repair, and wound healing. 1, 6 There are at least 23 members of the MMP family, sharing a basic domain structure consisting of pro-, catalytic, and hemopexin domains. The majority of MMPs do not have transmembrane domains, and utilize the hemopexin domain to engage with specific regions of cell membrane proteins in order to localize the MMP to a specific site of activity.
In a series of adhesion assays using washed platelets and recom- [Article updated on June 8, 2018 after first online publication on May 1, 2018: At the authors' request, the sentence "Treatment of platelets with MMP-13 disturbed RGD-sequence binding to αIIbβ3 but not collagen or CRP binding to GPVI" was updated to "Treatment of platelets with MMP-13 disturbed αIIbβ3-and GPVI-mediated adhesion to immobilized fibrinogen and CRP respectively. However MMP-13 did not interfere with GPVI-mediated secretion and higher concentrations of GPVI ligands overcame MMP-13 disruption of GPVI activation in platelet suspensions."] to be implicated in hemostasis via platelet function and thrombus formation (Table 1 ). Both MMP-1 (present on human but not murine platelets), and MMP-2 (present on both), localize to the platelet surface by allosteric engagement with the platelet-specific integrin αIIbβ3 and amplify platelet activation and thrombus formation under arterial shear rates. 8, 9 The MMP-1 and -2 modes of action involve a metalloproteinase-driven proteolysis of proteaseactivated receptor (PAR) 1, at two sites proximal to, but distinct from, the thrombin cleavage site in PAR1. [10] [11] [12] Platelets from MMP-2-deficient mice showed impaired aggregation to low doses of agonists targeting G-protein coupled receptors and reduced adhesion to collagen. Addition of pro-MMP2 to MMP-2-deficient platelets restored platelet function and MMP-2-deficient mice also showed reduced thrombosis in a thromboembolism model. 11 MMP-2 has been implicated in human thrombotic conditions, with elevated levels of MMP-2 observed in blood samples from acute coronary syndrome patients. 13 Platelets also express MMP-14, which has a transmembrane domain and is often found in complex with pro-MMP-2 and an associated inhibitor, tissue inhibitor of metalloproteinase (TIMP)-2. 8, 14, 15 Whether MMP-9 is produced by platelets or originates from external sources and simply binds to platelets remains a matter of some conjecture, 16, 17 and the anti-aggregatory effects of MMP-9 on platelets remain to be elucidated.
A number of the MMPs are noted to have catalytic activity at the platelet surface, and in the case of MMP-2, intracellular cleavage of talin 18 which may contribute to transmission of inside-out signals leading to αIIbβ3 activation. Here, 2 the mechanism of action of MMP-13 on platelets did not seem to involve direct cleavage of GPVI or αIIbβ3. Whilst MMP-13 could cleave recombinant purified forms of GPVI and αIIbβ3, as well as purified fibrinogen, treatment of platelets with MMP-13 did not result in release of GPVI or αIIbβ3. Howes and colleagues included data that indicate that MMP-13 is involved in cooperative binding to both GPVI and αIIbβ3 (Figure 1 ).
Treatment of platelets with MMP-13 disturbed αIIbβ3-and GPVImediated adhesion to immobilized fibrinogen and CRP respectively.
However MMP-13 did not interfere with GPVI-mediated secretion and higher concentrations of GPVI ligands overcame MMP-13 disruption of GPVI activation in platelet suspensions. This implies that MMP-13 engages with GPVI at a site that is distinct from the ligand binding region. In support of this, the anti-GPVI single chain antibody 1C3 disrupted washed platelet adhesion to MMP-13. 1C3
recognizes an epitope that includes amino acids residing in the second immunoglobulin-like domain of GPVI and in previous studies, treatment of platelets with 1C3 did not alter thrombus size, surface area, or morphology on collagen, but could interfere with GPVI clustering. 20 Further, MMP-13 was found to bind strongly to the dimeric form of GPVI over monomeric GPVI, and that there was minimal binding to integrin α2β1, a finding that is somewhat unexpected given that α2β1 binds other MMPs 14 and co-localizes with GPVI dimer clusters. 21 Taken together, these data suggest that MMP-13 may influence GPVI function by interfering with the lateral movement of GPVI preventing receptor clustering, but not blocking the ligand-binding site of GPVI.
Matrix metalloproteinase-13 has an emerging role in pathobiology of cancer, arthritis, and in cardiovascular disease. 3 MMP-13
was originally isolated from breast carcinomas and is upregulated in premetastatic niches, and levels of MMP-13 correlate positively with stroke progression and are implicated as contributing to enhanced plaque vulnerability and rupture. 22 Taken together, data presented by Howes and colleagues suggest that MMP-13
could have a regulatory function to limit platelet activation. This process, however, will rely on significant local concentrations of 
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